[
  {
    "ts": "2025-11-24T12:45:00+00:00",
    "headline": "RVL Pharmaceuticals Announces Leadership Appointments to Accelerate Next Phase of Growth and Commercial Momentum",
    "summary": "RVL Pharmaceuticals, Inc and its affiliates (together, \"RVL\") today announced a series of senior leadership appointments to strengthen the organization and position the company for accelerated growth across its business, including its flagship product, Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1%.",
    "url": "https://finance.yahoo.com/news/rvl-pharmaceuticals-announces-leadership-appointments-124500429.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "1d8d0747-1d94-3b4e-9c56-5bb146867a46",
      "content": {
        "id": "1d8d0747-1d94-3b4e-9c56-5bb146867a46",
        "contentType": "STORY",
        "title": "RVL Pharmaceuticals Announces Leadership Appointments to Accelerate Next Phase of Growth and Commercial Momentum",
        "description": "",
        "summary": "RVL Pharmaceuticals, Inc and its affiliates (together, \"RVL\") today announced a series of senior leadership appointments to strengthen the organization and position the company for accelerated growth across its business, including its flagship product, Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1%.",
        "pubDate": "2025-11-24T12:45:00Z",
        "displayTime": "2025-11-24T12:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/80efeb6a95ce099da2d60c9bf9629f50",
          "originalWidth": 16,
          "originalHeight": 16,
          "caption": "Cision",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Rc80fgTAsLDaU9xn4TeSqQ--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/80efeb6a95ce099da2d60c9bf9629f50.cf.webp",
              "width": 16,
              "height": 16,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VZWM2VsT7coc_hFN.xjnzg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/80efeb6a95ce099da2d60c9bf9629f50.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/rvl-pharmaceuticals-announces-leadership-appointments-124500429.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/rvl-pharmaceuticals-announces-leadership-appointments-124500429.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "RVLPQ"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-24T15:56:00+00:00",
    "headline": "Hip Replacement Market Competitive Landscape Report 2025: Recent Developments, Strategies, Sustainability, Product Launches, Key Persons, and Revenue Forecasts",
    "summary": "The Hip Replacement industry is poised for substantial growth, projected to reach US$ 10.24 billion by 2033, up from US$ 6.92 billion in 2024, at a CAGR of 4.45% between 2025 and 2033. This expansion is driven by increased awareness of procedures such as hip arthroplasty, which helps alleviate discomfort and enhance mobility for those with severe joint disorders. Factors such as rising obesity, orthopedic issues, and demand for surgical treatments contribute to market growth. Key players driving",
    "url": "https://finance.yahoo.com/news/hip-replacement-market-competitive-landscape-155600543.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "7e91dd04-6053-3245-b598-73abd3f8d08e",
      "content": {
        "id": "7e91dd04-6053-3245-b598-73abd3f8d08e",
        "contentType": "STORY",
        "title": "Hip Replacement Market Competitive Landscape Report 2025: Recent Developments, Strategies, Sustainability, Product Launches, Key Persons, and Revenue Forecasts",
        "description": "",
        "summary": "The Hip Replacement industry is poised for substantial growth, projected to reach US$ 10.24 billion by 2033, up from US$ 6.92 billion in 2024, at a CAGR of 4.45% between 2025 and 2033. This expansion is driven by increased awareness of procedures such as hip arthroplasty, which helps alleviate discomfort and enhance mobility for those with severe joint disorders. Factors such as rising obesity, orthopedic issues, and demand for surgical treatments contribute to market growth. Key players driving",
        "pubDate": "2025-11-24T15:56:00Z",
        "displayTime": "2025-11-24T15:56:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/7f169766d73c837dd0a9f7743b3f4a9c",
          "originalWidth": 600,
          "originalHeight": 400,
          "caption": "Hip Replacement Market",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IljbCfTyN8nkuHSKwiFhvw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/7f169766d73c837dd0a9f7743b3f4a9c.cf.webp",
              "width": 600,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zRREBVg6LXAAG7EqCgmIsA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/7f169766d73c837dd0a9f7743b3f4a9c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/hip-replacement-market-competitive-landscape-155600543.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/hip-replacement-market-competitive-landscape-155600543.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SN.L"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "ZBH"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-24T15:29:00+00:00",
    "headline": "Biotech Stock Nanobiotix (NBTX) Is Up 660% This Year -- Here's Why the Rally Could Continue",
    "summary": "It has grown wildly, and it could keep growing.",
    "url": "https://www.fool.com/investing/2025/11/24/biotech-stock-nanobiotix-nbtx-is-up-660-this-year/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "6454d91d-49d6-36ef-ab7a-0f4106a0e23a",
      "content": {
        "id": "6454d91d-49d6-36ef-ab7a-0f4106a0e23a",
        "contentType": "STORY",
        "title": "Biotech Stock Nanobiotix (NBTX) Is Up 660% This Year -- Here's Why the Rally Could Continue",
        "description": "",
        "summary": "It has grown wildly, and it could keep growing.",
        "pubDate": "2025-11-24T15:29:00Z",
        "displayTime": "2025-11-24T15:29:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/b45e6f9c2ebebb69b4b72a0bff8cef2b",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "Four people are cheering and jumping.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Fw7.8l8JgJhr76ndo..CGw--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/b45e6f9c2ebebb69b4b72a0bff8cef2b.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kw0onKF3Rl14zRwXfhWqxw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/b45e6f9c2ebebb69b4b72a0bff8cef2b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/24/biotech-stock-nanobiotix-nbtx-is-up-660-this-year/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biotech-stock-nanobiotix-nbtx-660-152900321.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NANO.PA"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-24T17:37:14+00:00",
    "headline": "EXCLUSIVE: Sustainable Value Creation: Keynote Fireside with Trian Fund Management, 5th Palm Beach CorpGov Forum",
    "summary": "CorpGov and IPO Edge are pleased to provide complete video coverage of the fifth annual Palm Beach CorpGov Forum held on Nov. 5-6, featuring keynote speaker Josh Frank, Partner and Co-Chief Investment Officer at Wall Street legend Nelson Peltz’s Trian Fund Management. Mr. Frank discussed Trian’s position for the last six years at Unilever PLC […] The post EXCLUSIVE: Sustainable Value Creation: Keynote Fireside with Trian Fund Management, 5th Palm Beach CorpGov Forum appeared first on CorpGov.",
    "url": "https://finance.yahoo.com/news/exclusive-sustainable-value-creation-keynote-173714344.html",
    "source": "CorpGov.com",
    "provider": "yfinance",
    "raw": {
      "id": "fd739971-edef-3b65-97e7-f4bbf26bc985",
      "content": {
        "id": "fd739971-edef-3b65-97e7-f4bbf26bc985",
        "contentType": "STORY",
        "title": "EXCLUSIVE: Sustainable Value Creation: Keynote Fireside with Trian Fund Management, 5th Palm Beach CorpGov Forum",
        "description": "",
        "summary": "CorpGov and IPO Edge are pleased to provide complete video coverage of the fifth annual Palm Beach CorpGov Forum held on Nov. 5-6, featuring keynote speaker Josh Frank, Partner and Co-Chief Investment Officer at Wall Street legend Nelson Peltz’s Trian Fund Management. Mr. Frank discussed Trian’s position for the last six years at Unilever PLC […] The post EXCLUSIVE: Sustainable Value Creation: Keynote Fireside with Trian Fund Management, 5th Palm Beach CorpGov Forum appeared first on CorpGov.",
        "pubDate": "2025-11-24T17:37:14Z",
        "displayTime": "2025-11-24T17:37:14Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/corpgov_com_597/948eab36b483d8ba083da25909c9ed7c",
          "originalWidth": 1371,
          "originalHeight": 676,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_iLWdGX1pjwzhCa8p6iKzA--~B/aD02NzY7dz0xMzcxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/corpgov_com_597/948eab36b483d8ba083da25909c9ed7c.cf.webp",
              "width": 1371,
              "height": 676,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0fR3u52E0uBViW5lMxMxdg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/corpgov_com_597/948eab36b483d8ba083da25909c9ed7c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "CorpGov.com",
          "url": "http://corpgov.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/exclusive-sustainable-value-creation-keynote-173714344.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/exclusive-sustainable-value-creation-keynote-173714344.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PSKY"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "PG"
            },
            {
              "symbol": "UL"
            },
            {
              "symbol": "UNLYF"
            },
            {
              "symbol": "DIS"
            },
            {
              "symbol": "ULVR.L"
            },
            {
              "symbol": "KDP"
            },
            {
              "symbol": "MDLZ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-24T21:15:00+00:00",
    "headline": "Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook",
    "summary": "Financial foundation toward self-sustained long-term growth established with the closing with HealthCare Royalty (“HCRx”) of a non-dilutive royalty financing valued up to $71 millionProgress in the JNJ-1900 (NBTXR3) global development program announced including first data from a Phase 1 esophageal cancer study sponsored by The University of Texas MD Anderson Cancer Center (“MD Anderson”)Completed the NANORAY-312 sponsorship transfer to Johnson & Johnson in the majority of regionsAdvanced the Cu",
    "url": "https://finance.yahoo.com/news/nanobiotix-provides-third-quarter-2025-211500646.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "8012ed5b-5993-3d04-9ed3-bbd9829ff665",
      "content": {
        "id": "8012ed5b-5993-3d04-9ed3-bbd9829ff665",
        "contentType": "STORY",
        "title": "Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook",
        "description": "",
        "summary": "Financial foundation toward self-sustained long-term growth established with the closing with HealthCare Royalty (“HCRx”) of a non-dilutive royalty financing valued up to $71 millionProgress in the JNJ-1900 (NBTXR3) global development program announced including first data from a Phase 1 esophageal cancer study sponsored by The University of Texas MD Anderson Cancer Center (“MD Anderson”)Completed the NANORAY-312 sponsorship transfer to Johnson & Johnson in the majority of regionsAdvanced the Cu",
        "pubDate": "2025-11-24T21:15:00Z",
        "displayTime": "2025-11-24T21:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/877bc3c248fcc3ff682764dded227a6f",
          "originalWidth": 926,
          "originalHeight": 309,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0TYJr3g253ajy.o1ds4uaQ--~B/aD0zMDk7dz05MjY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/877bc3c248fcc3ff682764dded227a6f.cf.webp",
              "width": 926,
              "height": 309,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/X40EZNtxNk_.fUKkGmiBRQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/877bc3c248fcc3ff682764dded227a6f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/nanobiotix-provides-third-quarter-2025-211500646.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/nanobiotix-provides-third-quarter-2025-211500646.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NANO.PA"
            },
            {
              "symbol": "NBTX"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-24T18:53:00+00:00",
    "headline": "BAYRYs Cardiovascular Drug Hits Goals in Late-Stage Study",
    "summary": "Bayer's asundexian hits key goals in the OCEANIC-STROKE study, showing reduced ischemic stroke risk without added major bleeding.",
    "url": "https://finance.yahoo.com/news/bayrys-cardiovascular-drug-hits-goals-185300559.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "340c74d0-d23f-38bd-97aa-869e6accab46",
      "content": {
        "id": "340c74d0-d23f-38bd-97aa-869e6accab46",
        "contentType": "STORY",
        "title": "BAYRYs Cardiovascular Drug Hits Goals in Late-Stage Study",
        "description": "",
        "summary": "Bayer's asundexian hits key goals in the OCEANIC-STROKE study, showing reduced ischemic stroke risk without added major bleeding.",
        "pubDate": "2025-11-24T18:53:00Z",
        "displayTime": "2025-11-24T18:53:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/50c06d1d19c16cb71d6cb49028119372",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5pnU3NQ.800lSpcRBKjZNg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/50c06d1d19c16cb71d6cb49028119372.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/W2_ZZ2Pl7OVNL4tXoICDoQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/50c06d1d19c16cb71d6cb49028119372.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bayrys-cardiovascular-drug-hits-goals-185300559.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bayrys-cardiovascular-drug-hits-goals-185300559.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "BAYRY"
            },
            {
              "symbol": "BAYZF"
            },
            {
              "symbol": "BAYN.DE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]